AstraZeneca PLC (LSE/STO/NYSE: AZN) announced on 16 November 2026 that the European Commission has approved Klygefa (gefurulimab), developed through its Alexion rare disease division, for the treatment of adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive. The approval makes Klygefa the first and only dual-binding nanobody C5 inhibitor authorised in the European Union, offering once-weekly subcutaneous self-administration via autoinjector. The decision is significant for investors tracking AstraZeneca's rare disease pipeline, as it extends Klygefa's commercial reach into one of the world's largest pharmaceutical markets.

Key Points

  • AstraZeneca PLC (AZN) — global biopharmaceutical company headquartered in Cambridge, UK
  • European Commission has approved Klygefa (gefurulimab) as add-on therapy for AChR antibody-positive adults with generalised myasthenia gravis
  • Approval based on the PREVAIL Phase III trial, which enrolled 260 patients across 20 countries; primary endpoint met with MG-ADL score improvement at week 26 (treatment difference: -1.6, p<0.0001)
  • Investors may watch progress of regulatory submissions currently under review in China and additional countries

PREVAIL Phase III Trial Data Underpinning the European Commission's Klygefa Decision

The European Commission's approval was based on results from the PREVAIL Phase III trial, a global, randomised, double-blind, placebo-controlled study evaluating gefurulimab in 260 patients recruited from 20 countries across North America, Europe, Asia, and the Pacific region. The trial met its primary endpoint, demonstrating a statistically significant improvement from baseline in the Myasthenia Gravis Activities of Daily Living total score at week 26 compared to placebo, with a treatment difference of -1.6 (95% CI: -2.4, -0.8; p<0.0001). A clinically meaningful improvement was observed as early as week one and was sustained through week 26. The data were published in JAMA Neurology.

Klygefa's Dual-Binding Nanobody Mechanism Distinguishes It Within EU's gMG Treatment Landscape

Klygefa works by binding to the C5 protein in the terminal complement cascade, inhibiting the immune system's uncontrolled attack on the neuromuscular junction. Its concurrent binding to serum albumin extends its half-life, enabling once-weekly dosing — a differentiating feature compared with existing complement inhibitors. The announcement states Klygefa's safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG, and that the medicine was generally well-tolerated. This positions Klygefa as the first and only dual-binding nanobody C5 inhibitor approved in the EU, adding a novel mechanism to the existing treatment toolkit for physicians managing this complex rare disease.

Alexion Targets an Estimated 66,000 AChR-Positive gMG Patients Across Five Key European Markets

AstraZeneca's Alexion division estimates approximately 82,500 people are diagnosed with gMG across Germany, France, the UK, Italy, and Spain, with around 66,000 being AChR-positive — the specific population for whom Klygefa is approved. Generalised myasthenia gravis is a rare autoimmune disorder causing severe muscle weakness and reduced muscle function, with symptoms potentially including respiratory failure. Klygefa is already approved in the US, Japan, and other countries for certain adults with gMG, and regulatory submissions based on PREVAIL results remain under review in China and additional markets, indicating further potential geographic expansion for the product.